Trial Profile
Phase I, Open-Label Study in Healthy Male Subjects Describing GSK1349572 Exposure in Blood Plasma, Seminal Fluid and Rectal Mucosal Tissue Following Single and Multiple Dosing.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 23 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2011 New trial record